HALO
NASDAQ
US
Halozyme Therapeutics, Inc. - Common Stock
$64.49
▼ $-0.91
(-1.39%)
Vol 1.5M
12
Quality Score
ok
Deep Check
2/5
ok
Rev ✓
NI ✓
>IPO ✗
Mkt Cap
$7.9B
P/E
13.3
ROE
141.6%
Margin
47.9%
D/E
299.80
Beta
0.97
52W
$47–$80
Wall Street Consensus
15 analysts · Apr 20262
Strong Buy
9
Buy
3
Hold
1
Sell
0
Strong Sell
73.3%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $2.24 | $-0.24 | $-2.48 |
| Sep 2025 | $1.66 | $1.72 | +$0.06 |
| Jun 2025 | $1.29 | $1.54 | +$0.25 |
| Mar 2025 | $0.97 | $1.11 | +$0.14 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $298.0M | $264.9M | $325.7M | $354.3M | $451.8M |
| Net Income | — | $137.0M | $118.1M | $165.2M | $175.2M | -$141.6M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 136.6% | 136.6% | 136.6% | 136.6% | 141.6% | 141.6% |
| P/E (TTM) | 11.50 | 14.64 | 15.81 | 13.68 | 13.14 | 13.29 |
| Net Margin | 50.7% | 47.3% | 47.3% | 47.3% | 47.9% | 47.9% |
| Gross Margin | 85.8% | 84.2% | 84.2% | 84.2% | 84.5% | 84.5% |
| D/E Ratio | 453.53 | 453.53 | 453.53 | 453.53 | 299.80 | 299.80 |
| Current Ratio | 8.36 | 8.36 | 8.36 | 8.36 | 1.59 | 1.59 |
Key Ratios
ROA (TTM)
27.9%
P/S (TTM)
6.37
P/B
16.7
EPS (TTM)
$4.76
CF/Share
$2.37
Rev Growth 3Y
+31.8%
52W High
$79.50
52W Low
$46.76
$46.76
52-Week Range
$79.50
Financial Health
Free Cash Flow
-$70.2M
Net Debt
$2.0B
Cash
$133.8M
Total Debt
$2.1B
As of Dec 31, 2025
How does HALO compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
HALO valuation vs Biotechnology peers
P/E ratio
13.3
▼
29%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
6.4
▼
50%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
16.7
▲
580%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
HALO profitability vs Biotechnology peers
ROE
141.6%
▲
310%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
47.9%
▲
117%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
84.6%
▲
8%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
27.9%
▲
160%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
HALO financial health vs Biotechnology peers
D/E ratio
299.8
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
1.6
▼
64%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
1.0
▼
0%
below
peers
(1.0)
vs Peers
vs Industry
Less volatile
HALO fundamentals radar
HALO
Peer median
Industry
HALO profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
HALO vs peers: key metrics
Latest AI Opinion
Grok
BUY
Price action shows a significant pullback from the February 2026 high of $82.22 to the current $64.19, representing about a 22% dip, which appears to be testing support around $62-64 seen in prior lows, making this a potentially attractive entry …
Mar 23, 2026Latest News
No related news yet